Tag: Asthma

Understanding the Impact of Inhaled Corticosteroids on Adverse Events in People with Asthma

Asthma is a chronic condition that affects many millions of people worldwide, making it difficult for them to breathe due to inflamed airways. Inhaled corticosteroids (ICS) are a cornerstone of asthma treatment, significantly improving patients’ quality of life by reducing symptoms, preventing asthma attacks, and improving lung function. However, while the benefits of ICS are well-established, there are concerns about potential adverse effects, particularly at higher doses.

The Role of Inhaled Corticosteroids

Inhaled corticosteroids are anti-inflammatory medications that are commonly prescribed to manage asthma. They work by reducing inflammation in the airways, making it easier to breathe and reducing the frequency of asthma exacerbations. According to current guidelines, patients should use the lowest effective dose of ICS to manage their asthma effectively.

Key Findings from Our Recent Research Study

Our recent study in the American Journal of Respiratory and Critical Care Medicine has shed light on the association between the dose of ICS and the frequency of adverse events. The study, which analysed data from two large UK nationwide databases, aimed to determine the risk of adverse effects from short-term ICS use in people with asthma. We found that:

Low-Dose ICS: Short-term use of low-dose ICS (≤200mcg per day) was not associated with significant adverse effects.

Medium-High Dose ICS: Use of medium (201-599mcg per day) and high doses (≥600mcg per day) of ICS was associated with an increased risk of several adverse outcomes, including major adverse cardiac events (MACE), arrhythmia, pulmonary embolism (PE), and pneumonia. The risk increased with higher doses.

Major Adverse Cardiac Events (MACE): We found that medium and high doses of ICS were associated with a significantly increased risk of MACE. For medium doses, the hazard ratio (HR) was 2.63, and for high doses, it was 4.63.

Arrhythmia: Similarly, the risk of arrhythmia was higher with medium doses (HR 2.21) and even more so with high doses (HR 2.91).

Pulmonary Embolism (PE): The risk of PE was also elevated, with hazard ratios of 2.10 for medium doses and 3.32 for high doses.

Pneumonia: We study found an increased risk of pneumonia at both medium (HR 2.25) and high doses (HR 4.09).

These findings highlight the importance of adhering to guideline recommendations to use the lowest effective ICS dose to manage asthma, thereby minimizing the risk of adverse events.

Implications for Asthma Management

Our study emphasises the need for clinicians to balance the benefits of ICS in controlling asthma with the potential risks associated with higher doses. Here are some key takeaways for both healthcare providers and patients:

Personalized Treatment Plans: Healthcare providers should tailor asthma treatment plans to each patient, ensuring that the ICS dose is sufficient to control symptoms while minimizing potential risks.

Regular Reviews: Regular asthma reviews and medication assessments should be conducted to ensure that patients are on the lowest effective dose of ICS. This includes considering step-down approaches when asthma is well-controlled.

Patient Education: Patients should be educated about the importance of adhering to their prescribed treatment and the potential risks of using higher doses of ICS without medical guidance.

Conclusion

Inhaled corticosteroids remain a vital component of asthma management, offering significant benefits in reducing symptoms and preventing exacerbations. However, this recent research underscores the importance of using the lowest effective dose to mitigate the risk of adverse events. By working closely with healthcare providers, patients can ensure that their asthma is managed effectively and safely. Finally, as we continue to learn more about the long-term effects of asthma medications, ongoing research and vigilance are crucial in optimizing treatment strategies for better health outcomes.

Global deaths, prevalence and disability for chronic obstructive pulmonary disease and asthma

A recent paper from the Global Burden of Disease (GBD) Chronic Respiratory Disease Collaborators examined the burden of ill-health caused by chronic obstructive pulmonary disease (COPD) and asthma. The paper was published in the journal The Lancet Respiratory Medicine.

COPD and asthma are common diseases with a heterogeneous distribution worldwide. In the paper, we presented findings for COPD and asthma from the Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2015 study. The GBD study provides annual updates on estimates of deaths, prevalence, and disability for over 300 diseases and injuries, for 188 countries from 1990 to the most recent year.

We found that in 2015, 3.2 million people died from COPD worldwide, an increase of 11·6% compared with 1990. There was a decrease in age-standardised death rate of 41·9% but this was counteracted by population growth and ageing of the global population. From 1990 to 2015, the prevalence of COPD increased by 44%, whereas age-standardised prevalence decreased by 14·7%.

In 2015, 0·4 million people died from asthma globally, a decrease of 26·7% from 1990. The age-standardised death rate decreased by 58·8% (39·0 to 69·0). The prevalence of asthma increased by 12·6% whereas the age-standardised prevalence decreased by 17·7%.

Smoking and ambient particulate matter were the main risk factors for COPD followed by household air pollution, occupational particulates, ozone, and second-hand smoke. Together, these risks explained 73% of disability due to COPD. Smoking and occupational asthma precipitants were the only risks quantified for asthma in GBD, accounting for 16.5% (disability due to asthma.

In conclusion, asthma was the commonest chronic respiratory disease worldwide in 2015, with twice the number of cases of COPD. Deaths from COPD were eight times more common than deaths from asthma.

We also concluded that although there are laudable international collaborative efforts to make surveys of asthma and COPD more comparable, no consensus exists on case definitions and how to measure disease severity for population health measurements like GBD. Comparisons between countries and over time are important, as much of the chronic respiratory burden is either preventable or treatable with affordable interventions.

https://doi.org/10.1016/S2213-2600(17)30293-X